febuxostat has been researched along with Innate Inflammatory Response in 12 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 6 (50.00) | 24.3611 |
2020's | 6 (50.00) | 2.80 |
Authors | Studies |
---|---|
Farzipour, S; Ghasemi, A; Hosseinimehr, SJ; Raeispour, M; Talebpour Amiri, F | 1 |
Chiba, K; Iino, T; Kataoka, T; Odake, K; Sudo, A; Tsujii, M | 1 |
Hayashi, T; Hiramitsu, S; Hisatome, I; Jinnouchi, H; Kakuda, H; Kawai, N; Kimura, K; Kojima, S; Matsui, K; Mori, H; Ogawa, H; Ohya, Y; Saito, Y; Sugawara, M; Tokutake, E; Tsujita, K; Uchiyama, K; Wakasa, Y; Waki, M; Yokota, N | 1 |
Du, YW; Li, XN; Liu, HB; Wang, TT; Wang, W | 1 |
Bittleman, D; Coras, R; Dadpey, B; Guma, M; Hamilton, B; Lauro, K; Liu-Bryan, R; Mikuls, TR; Quehenberger, O; Reilly, SM; Terkeltaub, R; Thorisdottir, H | 1 |
Busso, N; Kobayashi, T; Nomura, J; So, A | 1 |
Bang, D; Curovic, F; Igel, TF; Katz, SD; Krasnokutsky, S; Lazaro, D; Oh, C; Pike, VC; Pillinger, MH; Romero, AG; Shah, B; Toprover, M | 1 |
Ahmed, AAE; Ahmed, MAE; El Morsy, EM | 1 |
Busso, N; Ives, A; Nomura, J; So, A; Tamura, M; Tsujimoto, S; Yamanaka, Y | 1 |
Busso, N; Ives, A; Kobayashi, T; Matsui, C; Nomura, J; Shirakura, T; So, A; Tamura, M; Tsujimoto, S; Yamanaka, Y | 1 |
Agrawal, A; Saigal, R | 1 |
Alonso-Pacho, A; de la Puerta González-Quevedo, C; Fabregate-Fuente, M; Sabán-Ruiz, J | 1 |
2 review(s) available for febuxostat and Innate Inflammatory Response
Article | Year |
---|---|
Pathogenesis and Clinical Management of Gouty Arthritis.
Topics: Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Gouty; Colchicine; Diet, Healthy; Febuxostat; Fluid Therapy; Gout Suppressants; Humans; Hyperuricemia; Inflammation; Interleukin 1 Receptor Antagonist Protein; Polyethylene Glycols; Smoking Cessation; Urate Oxidase; Uric Acid; Uricosuric Agents; Xanthine Oxidase | 2015 |
Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Febuxostat; Heart Failure; Humans; Inflammation; Ischemia; Rabbits; Rats; Renal Insufficiency, Chronic; Thiazoles; Treatment Outcome; Xanthine Oxidase | 2013 |
1 trial(s) available for febuxostat and Innate Inflammatory Response
Article | Year |
---|---|
C-reactive Protein Levels and Cardiovascular Outcomes After Febuxostat Treatment in Patients with Asymptomatic Hyperuricemia: Post-hoc Analysis of a Randomized Controlled Study.
Topics: Atherosclerosis; C-Reactive Protein; Febuxostat; Female; Humans; Hyperuricemia; Inflammation; Male; Treatment Outcome; Uric Acid | 2023 |
9 other study(ies) available for febuxostat and Innate Inflammatory Response
Article | Year |
---|---|
Febuxostat, an inhibitor of xanthine oxidase, ameliorates ionizing radiation-induced lung injury by suppressing caspase-3, oxidative stress and NF-κB.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Caspase 3; Febuxostat; Inflammation; Lung Injury; Mice; NF-kappa B; Oxidative Stress; Radiation, Ionizing; Xanthine Oxidase | 2022 |
Febuxostat treatment attenuates oxidative stress and inflammation due to ischemia-reperfusion injury through the necrotic pathway in skin flap of animal model.
Topics: Animals; Disease Models, Animal; Febuxostat; Inflammation; Necrosis; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reperfusion Injury | 2021 |
Inhibition of Xanthine Oxidase Protects against Sepsis-Induced Acute Kidney Injury by Ameliorating Renal Hypoxia.
Topics: Acute Kidney Injury; Animals; Febuxostat; Hypoxia; Inflammation; Ischemia; Kidney; Lipopolysaccharides; Mice; Oxygen; Reactive Oxygen Species; RNA, Small Interfering; Sepsis; Xanthine Oxidase | 2022 |
Xanthine oxidase inhibitor urate-lowering therapy titration to target decreases serum free fatty acids in gout and suppresses lipolysis by adipocytes.
Topics: Adipocytes; Allopurinol; Colchicine; Enzyme Inhibitors; Fatty Acids, Nonesterified; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Inflammation; Lipolysis; Prospective Studies; Uric Acid; Xanthine Oxidase | 2022 |
Febuxostat, a Xanthine Oxidoreductase Inhibitor, Decreases NLRP3-dependent Inflammation in Macrophages by Activating the Purine Salvage Pathway and Restoring Cellular Bioenergetics.
Topics: Animals; Anti-Inflammatory Agents; Cells, Cultured; Energy Metabolism; Febuxostat; Humans; Inflammasomes; Inflammation; Macrophages; Mice; Mitochondria; NLR Family, Pyrin Domain-Containing 3 Protein; Primary Cell Culture; Purines; Reactive Oxygen Species; Xanthine Dehydrogenase | 2019 |
Initiating guideline-concordant gout treatment improves arterial endothelial function and reduces intercritical inflammation: a prospective observational study.
Topics: Allopurinol; Febuxostat; Gout; Gout Suppressants; Humans; Hyperuricemia; Inflammation | 2020 |
Protective effects of febuxostat against paraquat-induced lung toxicity in rats: Impact on RAGE/PI3K/Akt pathway and downstream inflammatory cascades.
Topics: Acute Lung Injury; Animals; beta Catenin; Febuxostat; Inflammation; Lung; Lung Injury; Male; Oxidative Stress; Paraquat; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pulmonary Edema; Rats; Rats, Wistar; Receptor for Advanced Glycation End Products; Xanthine Oxidase | 2019 |
Febuxostat, an inhibitor of xanthine oxidase, suppresses lipopolysaccharide-induced MCP-1 production via MAPK phosphatase-1-mediated inactivation of JNK.
Topics: Animals; Cell Line, Tumor; Chemokine CCL2; Dual Specificity Phosphatase 1; Febuxostat; Female; Humans; Inflammation; Lipopolysaccharides; Macrophages; MAP Kinase Kinase 4; Mice; Mice, Inbred C57BL; Phosphorylation; Reactive Oxygen Species; RNA, Messenger; Thiazoles; Xanthine Oxidase | 2013 |
Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Body Weight; Cholesterol; Cytokines; Disease Models, Animal; Endothelial Cells; Febuxostat; Gout Suppressants; Inflammation; L-Lactate Dehydrogenase; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Plaque, Atherosclerotic; Reactive Oxygen Species; Thiazoles; Xanthine Oxidase | 2014 |